AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27711088 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tryptophan, Satureja montana, Tribulus terrestris, Phyllanthus emblica extracts
Number of subjects: 0
Study 27711088 — intervention group
Group type: COMPARATOR
Intervention: Counseling and sexual behavioral treatment (Control Group B)
Number of subjects: 0
Study 24890456 — intervention group
Group type: EXPERIMENTAL
Intervention: Looking during needle insertion
Number of subjects: 192
Study 24890456 — intervention group
Group type: EXPERIMENTAL
Intervention: Looking away during needle insertion
Number of subjects: 192
Study 24890456 — intervention group
Group type: COMPARATOR
Intervention: Sharp scratch verbal cue
Number of subjects: 192
Study 24890456 — intervention group
Group type: COMPARATOR
Intervention: Ready? verbal cue
Number of subjects: 192
Study 24160714 — intervention group
Group type: EXPERIMENTAL
Intervention: CLiAC program (intervention)
Number of subjects: 24
Study 24160714 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 24
Study 19931950 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based learning unit
Number of subjects: 0
Study 19931950 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture
Number of subjects: 0
Study 18172652 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal osteoporotic women
Number of subjects: 70
Study 18172652 — intervention group
Group type: COMPARATOR
Intervention: Healthy young women
Number of subjects: 70
Study 16242246 — intervention group
Group type: EXPERIMENTAL
Intervention: Action plans
Number of subjects: 223
Study 16242246 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 223
Study 16242246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention
Number of subjects: 223
Study 16242246 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 223
Study 12519412 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily
Number of subjects: 34
Study 12519412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 10735260 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8709603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ru He Chong Ji
Number of subjects: 280
Study 2719349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfite
Number of subjects: 1
Study 2719349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 363229 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine plus prednisone (2.5 mg/kg body weight daily)
Number of subjects: 25
Study 363229 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 25
Study 31539169 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) - 6 weekly 2-hour group sessions
Number of subjects: 91
Study 31539169 — intervention group
Group type: COMPARATOR
Intervention: Survivorship Education (SE) - 6 weekly 2-hour group sessions
Number of subjects: 91
Study 31539169 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) - one 30-minute group coaching session with survivorship readings
Number of subjects: 91
Study 31539169 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 91
Study 28682439 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural anesthesia
Number of subjects: 92
Study 28682439 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 92
Study 25091596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate potassium concentration between 1.6 and 2.5 mEq/L
Number of subjects: 551
Study 25091596 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 551
Study 23797557 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinfection with alcohol 70% (w/v) without previous cleaning
Number of subjects: 0
Study 23797557 — intervention group
Group type: COMPARATOR
Intervention: Disinfection with alcohol 70% (w/v) preceded by cleaning
Number of subjects: 0
Study 21197586 — intervention group
Group type: EXPERIMENTAL
Intervention: palm olein
Number of subjects: 10
Study 21197586 — intervention group
Group type: EXPERIMENTAL
Intervention: olive oil
Number of subjects: 10
Study 21197586 — intervention group
Group type: COMPARATOR
Intervention: lard
Number of subjects: 10
Study 21197586 — intervention group
Group type: EXPERIMENTAL
Intervention: high fat load (50 g fat)
Number of subjects: 10
Study 18070658 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 40
Study 18070658 — intervention group
Group type: COMPARATOR
Intervention: ADA diet
Number of subjects: 40
Study 16544256 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus AS
Number of subjects: 528
Study 16544256 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus AQ
Number of subjects: 528
Study 16544256 — intervention group
Group type: EXPERIMENTAL
Intervention: AL (Coartem)
Number of subjects: 528
Study 16544256 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT (Artemisinin-based combination therapy)
Number of subjects: 528
Study 14693168 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-thrombotic syndrome assessment using a standardized score
Number of subjects: 153
Study 14693168 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective symptom assessment
Number of subjects: 153
Study 14693168 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective symptom assessment
Number of subjects: 153
Study 14693168 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor analysis for PTS development
Number of subjects: 153
Study 10902643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (HAART)
Number of subjects: 0
Study 10902643 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring CD4-cell counts and viral load
Number of subjects: 0
Study 10902643 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting HAART when CD4-cell count drops below 350 cells/microL
Number of subjects: 0
Study 8884421 — intervention group
Group type: EXPERIMENTAL
Intervention: Slideboard exercise (3 days per week, 1 hour each session, over a 10 week period)
Number of subjects: 25
Study 8884421 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 females)
Number of subjects: 25
Study 8317753 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia using isolated forearm technique with intravenous thiopental (3 mg/kg, 250 mg maximum) and succinylcholine (1.5 mg/kg), followed by a mixture of 50% N2O, 50% O2, and 0.5% halothane at a flow of 5 L/min and end‐tidal CO2 at 40 mm Hg. Paralysis maintained with a 0.1% succinylcholine infusion.
Number of subjects: 30
Study 2427405 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroids plus phenformin
Number of subjects: 0
Study 2427405 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29954701 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA tDCS
Number of subjects: 40
Study 29954701 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA tDCS
Number of subjects: 40
Study 29954701 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study 27134058 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomography Angiography (CTA)
Number of subjects: 71
Study 27134058 — intervention group
Group type: COMPARATOR
Intervention: Conventional Invasive Coronary Angiography (ICA)
Number of subjects: 71
Study 25035351 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamber X
Number of subjects: 0
Study 25035351 — intervention group
Group type: COMPARATOR
Intervention: IQ and Finn chambers
Number of subjects: 0
Study 23301437 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking About Live Kidney Donation (TALK) social worker intervention (SWI)
Number of subjects: 0
Study 20209200 — intervention group
Group type: EXPERIMENTAL
Intervention: One implant in the symphyseal area
Number of subjects: 36
Study 20209200 — intervention group
Group type: EXPERIMENTAL
Intervention: Two implants in the canine positions
Number of subjects: 36
Study 20209200 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 36
Study 18665190 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE (doxorubicin 50 mg/m(2) i.v., cyclophosphamide 1 g/m(2) i.v., etoposide 120 mg/m(2) i.v. on day 1, etoposide 240 mg/m(2) orally for 2 days)
Number of subjects: 280
Study 18665190 — intervention group
Group type: COMPARATOR
Intervention: PE (cisplatin 80 mg/m(2) and etoposide 120 mg/m(2) i.v. on day 1, etoposide 240 mg/m(2) orally for 2 days)
Number of subjects: 280
Study 18665190 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE
Number of subjects: 280
Study 18665190 — intervention group
Group type: COMPARATOR
Intervention: PE
Number of subjects: 280
Study 15875295 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block with 0.5 percent bupivacaine (n = 81)
Number of subjects: 163
Study 15875295 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia with 0.5 percent bupivacaine (n = 82)
Number of subjects: 163
Study 12885712 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein-hydrolysate formula (CH-1 or CH-2)
Number of subjects: 0
Study 12885712 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein-hydrolysate formula (CH-2)
Number of subjects: 0
Study 12885712 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysate formulas (CH-1 or CH-2)
Number of subjects: 0
Study 12885712 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein-hydrolysate formulas (CH-1 or CH-2)
Number of subjects: 0
Study 12885712 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-hydrolysate formula (WH)
Number of subjects: 0
Study 12885712 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 0
Study 10479004 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-shot SWL technique (Group 1; N = 30)
Number of subjects: 59
Study 10479004 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot SWL technique (Group 2; N = 29)
Number of subjects: 59
Study 8693524 — intervention group
Group type: EXPERIMENTAL
Intervention: Late reflush with organ preservation fluid
Number of subjects: 18
Study 8693524 — intervention group
Group type: COMPARATOR
Intervention: Control group (no late reflush)
Number of subjects: 18
Study 1744910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 1744910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment
Number of subjects: 0
Study 1744910 — intervention group
Group type: COMPARATOR
Intervention: Relaxation instructions
Number of subjects: 0
Study 6190545 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), 40 mg escalated to 60 mg/m2 IV push weekly
Number of subjects: 44
Study 6190545 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (DDP), 50 mg/m2 6 hour infusion days 1 and 8 every 4 weeks
Number of subjects: 44
Study 30624856 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant tablet (2 × 90-mg tablets)
Number of subjects: 87
Study 30624856 — intervention group
Group type: COMPARATOR
Intervention: Rolapitant capsule (4 × 45-mg capsules)
Number of subjects: 87
Study 30624856 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (tablet and capsule)
Number of subjects: 87
Study 29878040 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel plus carboplatin (nab-P/C)
Number of subjects: 191
Study 29878040 — intervention group
Group type: COMPARATOR
Intervention: nab-Paclitaxel plus gemcitabine (nab-P/G)
Number of subjects: 191
Study 29878040 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine plus carboplatin (G/C)
Number of subjects: 191
Study 26951105 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-guided goal-directed haemodynamic therapy (GDT)
Number of subjects: 180
Study 26951105 — intervention group
Group type: COMPARATOR
Intervention: Good standard clinical care (control)
Number of subjects: 180
Study 25123098 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing medical education for GPs (≥ 40 hours) in palliative care (PG)
Number of subjects: 68
Study 25123098 — intervention group
Group type: COMPARATOR
Intervention: Standard care without continuing education (CG)
Number of subjects: 68
Study 21813060 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 21813060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19463468 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-coated rapamycin-eluting stents
Number of subjects: 24
Study 19463468 — intervention group
Group type: COMPARATOR
Intervention: Nonpolymer rapamycin-eluting stents
Number of subjects: 24
Study 17214679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-type iontophoretic device
Number of subjects: 10
Study 17214679 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated palm)
Number of subjects: 10
Study 15500594 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐SBI (web-based assessment and personalized feedback)
Number of subjects: 104
Study 15500594 — intervention group
Group type: COMPARATOR
Intervention: Leaflet-only control group
Number of subjects: 104
Study 11340333 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+IL13+ lymphocytes from cord blood mononuclear cells (CBMC) derived from atopic mothers
Number of subjects: 208
Study 11340333 — intervention group
Group type: COMPARATOR
Intervention: Cord blood cytokine production (IFN-gamma, IL-4, IL-5)
Number of subjects: 208
Study 9740526 — intervention group
Group type: EXPERIMENTAL
Intervention: Medscand Endorette
Number of subjects: 152
Study 9740526 — intervention group
Group type: COMPARATOR
Intervention: Pipelle de Cornier
Number of subjects: 152
Study 9740526 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 152
Study 8312045 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter from general practitioner suggesting reduction in benzodiazepine use.
Number of subjects: 209
Study 8312045 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter from general practitioner plus four information sheets at monthly intervals.
Number of subjects: 209
Study 8312045 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 209
Study 2455011 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy (group I)
Number of subjects: 96
Study 2455011 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (group II)
Number of subjects: 96
Study 2455011 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (2 cycles)
Number of subjects: 96
Study 31282292 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-extremity power-training intervention (3 times per week for 6 weeks)
Number of subjects: 12
Study 31282292 — intervention group
Group type: COMPARATOR
Intervention: Rest-training (RT) group
Number of subjects: 12
Study 31282292 — intervention group
Group type: COMPARATOR
Intervention: Training-rest group
Number of subjects: 12
Study 29421165 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation group classes (Power of Breath, Sacred Sounds, Movement & Breath)
Number of subjects: 142
Study 29421165 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation group classes
Number of subjects: 142
Study 28838898 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 0
Study 28838898 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 26652592 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexplained chronic widespread pain
Number of subjects: 990
Study 26652592 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexplained chronic fatigue
Number of subjects: 990
Study 26652592 — intervention group
Group type: COMPARATOR
Intervention: Common associated factors for both conditions
Number of subjects: 990
Study 26652592 — intervention group
Group type: COMPARATOR
Intervention: Education and medical illnesses
Number of subjects: 990
Study 26652592 — intervention group
Group type: COMPARATOR
Intervention: Recent illness in a close relative, neuroticism, depression, and anxiety scores
Number of subjects: 990
Study 26652592 — intervention group
Group type: COMPARATOR
Intervention: Concurrent anxiety and/or depression
Number of subjects: 990
Study 23422921 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat or barley products providing 0.3-12.1 g β-glucan
Number of subjects: 34
Study 23422921 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed foods containing 4 g of β-glucan
Number of subjects: 34
Study 23422921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact grains
Number of subjects: 34
Study 23422921 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed foods
Number of subjects: 34
Study 21402653 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (25 minutes)
Number of subjects: 64
Study 21402653 — intervention group
Group type: COMPARATOR
Intervention: Resting control condition (reading for 25 minutes)
Number of subjects: 64
Study 19447268 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative testing (experimental group)
Number of subjects: 89
Study 19447268 — intervention group
Group type: COMPARATOR
Intervention: Solo testing (control group)
Number of subjects: 89
Study 16493102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting stent
Number of subjects: 1386
Study 16493102 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel‐eluting stent
Number of subjects: 1386
Study 12935409 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural blockade (TEB) with 0.5% lidocaine 3-5 ml every 2-4 hours for four weeks
Number of subjects: 30
Study 12935409 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine medicine only)
Number of subjects: 30
Study 16422030 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (1200 mg/day)
Number of subjects: 14
Study 16422030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16422030 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin and Placebo
Number of subjects: 14
Study 9187286 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacle present
Number of subjects: 6
Study 9187286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure level changes
Number of subjects: 6
Study 9187286 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructed level changes
Number of subjects: 6
Study 8444683 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg)
Number of subjects: 6
Study 8444683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3940792 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled atropine sulfate (0.075 mg/kg)
Number of subjects: 18
Study 30392186 — intervention group
Group type: EXPERIMENTAL
Intervention: ToyBox-intervention
Number of subjects: 3725
Study 26645117 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (T.C. PTNS)
Number of subjects: 70
Study 26645117 — intervention group
Group type: COMPARATOR
Intervention: Extended release oxybutynin (E.R.O.)
Number of subjects: 70
Study 25463664 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + a single episode of aPDT
Number of subjects: 20
Study 25463664 — intervention group
Group type: COMPARATOR
Intervention: SRP (Control Group)
Number of subjects: 20
Study 22999673 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic force of 0.980 N applied for 3 hours, 15 hours, 3 days, 12 days, or 21 days
Number of subjects: 64
Study 22999673 — intervention group
Group type: COMPARATOR
Intervention: Control group (contralateral teeth without orthodontic appliances)
Number of subjects: 64
Study 20116700 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure (group I)
Number of subjects: 93
Study 20116700 — intervention group
Group type: COMPARATOR
Intervention: Secondary closure (group II)
Number of subjects: 93
Study 17640058 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily)
Number of subjects: 546
Study 17640058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study 15649652 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 ml of black tea (acute)
Number of subjects: 66
Study 15649652 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 ml of black tea per day (chronic)
Number of subjects: 66
Study 15649652 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 66
Study 16259812 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg oestradiol patches (Evorel) used during the pill-free interval for two cycles
Number of subjects: 14
Study 16259812 — intervention group
Group type: COMPARATOR
Intervention: Placebo used during the pill-free interval for two cycles
Number of subjects: 14
Study 9558519 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro bur, retrograde filling and IRM
Number of subjects: 320
Study 9558519 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser treatment at apical and radicular portions
Number of subjects: 320
Study 9558519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic device for retrograde cavity preparation
Number of subjects: 320
Study 9558519 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser treatment at apical and radicular portions instead of micro bur
Number of subjects: 320
Study 7625112 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPwHBV vaccine administered in three doses (2 months apart)
Number of subjects: 42
Study 2152973 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber oat bran (87 g per day)
Number of subjects: 20
Study 2152973 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber refined wheat
Number of subjects: 20
Study 647185 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 28
Study 31740429 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based family-based weight loss treatment
Number of subjects: 266
Study 31740429 — intervention group
Group type: COMPARATOR
Intervention: Standard of care family-based weight loss treatment delivered in an academic medical center
Number of subjects: 266
Study 28949281 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-based mirror therapy (MT)
Number of subjects: 36
Study 28949281 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (Control)
Number of subjects: 36